Back to News
Market Impact: 0.6

Smith & Wesson Stock Slides as 4Q Sales, Profit Fall

SWBIFDS
InflationTax & TariffsConsumer Demand & RetailCorporate EarningsCorporate Guidance & OutlookCompany FundamentalsAnalyst Estimates
Smith & Wesson Stock Slides as 4Q Sales, Profit Fall

Smith & Wesson shares plummeted 19% to $8.79 after reporting a decline in Q4 profit to $8.6 million (19 cents per share) from $27.3 million (59 cents per share) year-over-year, with revenue falling 12% to $140.8 million, both figures missing analyst expectations. The company attributed the downturn to macroeconomic headwinds like tariffs and inflation impacting discretionary spending, and expects this trend to persist, leading them to limit inventory and withhold future guidance due to ongoing economic uncertainty.

Analysis

Smith & Wesson Brands, Inc. (SWBI) experienced a significant 19% decline in its stock price to $8.79 following the announcement of its fourth-quarter results, which underperformed both analyst expectations and prior-year figures. The company reported a profit of $8.6 million, or 19 cents per share, a stark reduction from $27.3 million, or 59 cents per share, recorded a year earlier. Adjusted earnings per share were 20 cents, failing to meet the 23 cents forecasted by analysts. Furthermore, revenue decreased by 12% to $140.8 million, missing the consensus estimate of $152.4 million. Management attributed these weaker results to adverse macroeconomic factors, specifically tariffs, inflation, and interest rates, which have curtailed discretionary spending. Smith & Wesson anticipates this trend of softer demand for firearms will continue, leading the company to limit its inventory and notably, to withhold future financial guidance due to prevailing uncertainties surrounding inflation and tariffs. This adds to a challenging period for the company, with its shares having already fallen 46% in the past 12 months, reflecting persistent headwinds.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo